How Parents of Patients Secured a Reprieve for Sarepta's Drug

The Parents’ Fight to Keep Elevidys on the Market

When health officials asked Sarepta Therapeutics Inc. to stop selling its gene therapy, Elevidys, for Duchenne muscular dystrophy, parents of affected children sprang into action. They traveled to Washington, D.C., met with members of Congress, and reached out to White House contacts. Others wrote directly to the Food and Drug Administration (FDA), demanding that the agency restore access to the drug. Despite a major trial failing to prove it slowed the disease’s progression, and in some cases, the treatment appearing to be deadly, these caregivers were determined to keep the therapy available.

For many families, the decision to seek out any possible treatment was driven by desperation. Duchenne muscular dystrophy is a genetic disorder that affects boys and young men, leading to progressive muscle weakening and atrophy. Most patients are in wheelchairs by their teens and may not live past their 30s. For parents like Caitlyn Butler, whose son was scheduled to receive Elevidys last month, the option to try the therapy was crucial.

Butter launched a Change.org petition demanding the FDA overturn its July directive, which eventually gained over 900 signatures. This activism, however, also benefited Sarepta, as the company funds some of the largest patient advocacy groups for the disease. These groups have long played a key role in persuading the FDA to approve Sarepta’s drugs through a regulatory shortcut that allows new therapies to be offered before definitive trials are complete.

The Role of Advocacy Groups and Political Influence

As the battle over Elevidys intensified, parents found support from powerful figures aligned with Donald Trump’s second administration. Senator Ron Johnson, known for his advocacy of unproven drugs for dying patients, and influencer Laura Loomer, who viewed a top FDA official as disloyal to the president, became vocal supporters of keeping the drug on the market. Their involvement helped sway the FDA, which reversed its decision after just 10 days.

The reversal came with consequences. Vinay Prasad, the FDA’s head of gene therapy and vaccines, resigned following intense criticism from conservative media. Sarepta’s stock and bond prices climbed, erasing most of the losses suffered in mid-July when the FDA initially asked the company to stop selling Elevidys, which costs $3.2 million per treatment.

However, the controversy raised concerns among experts about the growing influence of patient groups in drug approvals. Some worry that this trend could lead to the approval of treatments that may not be effective or could even be dangerous. Holly Fernandez Lynch, a professor of medical ethics at the University of Pennsylvania, warned that if the FDA simply follows patient demands without rigorous evaluation, it risks undermining its purpose.

Patient Advocacy and Ethical Dilemmas

Pat Furlong, founder of Parent Project Muscular Dystrophy, defended the right of patients to make informed decisions about their treatment options. She emphasized that families are aware of the risks and are willing to accept them. “Patients want options,” she said. “They want to discuss those options, both the benefits and the risks, with their clinicians, and make a decision that’s best for them.”

Sarepta maintained that it does not coordinate with advocacy groups but engages with them on various topics, including the status of Elevidys and access to the drug. The company provides sponsorship or grant support to nonprofit patient advocacy groups for efforts related to education and awareness. “Patients and families deserve the right to discuss with their physicians and make informed decisions about their treatment choices,” the company stated.

Despite the controversy, some families still believe the treatment is worth the risk. Caitlyn Butler, who authored the petition to keep Elevidys on the market, said her son made the final decision to try the therapy because he didn’t want to wait any longer. He received the treatment on August 7 and is recovering well, though tired.

The Broader Implications

The case of Elevidys highlights the complex interplay between patient advocacy, regulatory oversight, and corporate interests. While some families see the drug as a lifeline, others argue that the rush to approve treatments based on limited evidence can lead to harmful outcomes. The deaths of two teenagers from acute liver failure after receiving the drug have raised serious concerns about the safety of gene therapy.

As the debate continues, the question remains: How should regulators balance the need for innovation with the responsibility to protect patients? For now, Elevidys is back on the market, but the ethical dilemmas surrounding its use persist.